Transformando la práctica clínica del paciente con Cáncer de Pulmón ALK positivo

34 / 53

PFS benefit in patients with and without CNS
metastases at baseline*
Patients WITH CNS metastases at
baseline†
100
80
60
40
20
0
PFS (%)
Duration of PFS (months)
9 15 21 27 6 12 18 24 30 3 Day 1
7.4
(95% CI: 6.6–
9.6)
NR
(95% CI: 9.2–
NR)
Patients WITHOUT CNS metastases at baseline
PFS (%)
Duration of PFS (months)
9 15 21 27 6 12 18 24 30 3 Day 1
14.8
(95% CI: 10.8–
20.3)
NR
100
80
60
40
20
0
HR=0.40
p<0.0001
HR=0.51
p=0.0024
Alectinib (n=64)
Crizotinib (n=58)
Alectinib (n=88)
Crizotinib (n=93)